2008•Annals of OncologyOpen access

Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study

Enrique Aranda, M. Valladares, Maria Mercedes Martinez-Villacampa, Manuel Benavides, A. Gómez, B. Massutti, E. Marcuello, Manuel Constenla, Juan Carlos Cámara, Alfredo Carrato, Rosario Dueñas, Margarita Reboredo, M. Navarro, Eduardo Díaz‐Rubio

Open full text 27 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 27 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: FOLFIRI, Irinotecan, Medicine, Fluorouracil, Regimen, Internal medicine, Neutropenia, Gastroenterology

Back to paper search Browse research topics Original source

Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study — Research Paper | ScholarLens